2
Clinical Trials associated with MB-dNPM1-TCR.1(Miltenyi Biomedicine) / Not yet recruitingPhase 1/2 A Phase I/II Trial of MB-dNPM1-TCR.1 in HLA-A*02:01-positive Patients with Relapsed or Refractory NPM1-mutated AML to Determine Safety and Obtain First Data on Efficacy
The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A*02:01 in patients with relapsed or refractory AML.
100 Clinical Results associated with MB-dNPM1-TCR.1(Miltenyi Biomedicine)
100 Translational Medicine associated with MB-dNPM1-TCR.1(Miltenyi Biomedicine)
100 Patents (Medical) associated with MB-dNPM1-TCR.1(Miltenyi Biomedicine)
100 Deals associated with MB-dNPM1-TCR.1(Miltenyi Biomedicine)